Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB.

Permeability data from MDR1-MDCKII and PAMPA-BBB assays were compared to data from in situ brain perfusion to evaluate the accuracy of in vitro assays in predicting in vivo blood-brain barrier (BBB) permeability. PAMPA-BBB significantly correlated to in situ brain perfusion, however, MDR1-MDCKII had no correlation with in situ brain perfusion. PAMPA-BBB also significantly correlated with MDR1-MDCKII. The differential correlation of PAMPA-BBB and MDR1-MDCKII to in situ brain perfusion appears to be mainly due to the difference in membrane characteristics rather than binding to brain tissue. The MDR1-MDCKII cell membrane has lower ratios of: phospholipid to cholesterol, unsaturated to saturated acyl chains, and phosphatidyl-choline (PC) to sphingomyelin (SM) than brain endothelial cells, making it a poor passive permeability model for BBB. The BBB is more hydrophobic, rigid, and less fluidic than MDR1-MDCKII cell membrane. PAMPA-BBB more closely matches the BBB membrane in these characteristics and is a more accurate passive diffusion permeability model for BBB than MDR1-MDCKII. PAMPA-BBB is high throughput, low cost and has good prediction of in vivo BBB permeability, and therefore, it is a valuable tool in drug discovery to screen compounds for the rate of brain penetration.

[1]  S. Fleischer,et al.  Isolation of highly purified human and bovine brain endothelial cells and nuclei and their phospholipid composition , 1969, Lipids.

[2]  Maxime Culot,et al.  Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.

[3]  Li Di,et al.  Strategies to assess blood–brain barrier penetration , 2008, Expert opinion on drug discovery.

[4]  Alex Avdeef,et al.  Absorption and Drug Development: Solubility, Permeability, and Charge State , 2003 .

[5]  M. Lagarde,et al.  Fatty acid composition of brain capillary endothelial cells: effect of the coculture with astrocytes. , 1995, Journal of lipid research.

[6]  Cuiping Chen,et al.  P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[7]  Iain Martin,et al.  Prediction of blood-brain barrier penetration: are we missing the point? , 2004, Drug discovery today.

[8]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[9]  D. Scott,et al.  Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling. , 2002, Journal of pharmaceutical and biomedical analysis.

[10]  Phil Jeffrey,et al.  Improving the in Vitro Prediction of in Vivo Central Nervous System Penetration: Integrating Permeability, P-glycoprotein Efflux, and Free Fractions in Blood and Brain , 2006, Journal of Pharmacology and Experimental Therapeutics.

[11]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[12]  Stina Syvänen,et al.  On The Rate and Extent of Drug Delivery to the Brain , 2007, Pharmaceutical Research.

[13]  Meihua Tu,et al.  Development of a computational approach to predict blood-brain barrier permeability. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[14]  S. Hitchcock,et al.  Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.

[15]  Li Di,et al.  PAMPA--critical factors for better predictions of absorption. , 2007, Journal of pharmaceutical sciences.

[16]  P. Jeffrey,et al.  Challenges for blood–brain barrier (BBB) screening , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  D. Selivonchick,et al.  Lipid and fatty acyl composition of rat brain capillary endothelia isolated by a new technique , 1977, Lipids.

[18]  Li Di,et al.  Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. , 2004, Journal of pharmaceutical sciences.

[19]  Thomas J. Raub,et al.  In vitro models of the blood-brain barrier. , 1998, Alternatives to laboratory animals : ATLA.

[20]  A. Avdeef,et al.  PAMPA--a drug absorption in vitro model. 5. Unstirred water layer in iso-pH mapping assays and pKa(flux)--optimized design (pOD-PAMPA). , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  N. Dan,et al.  Effect of membrane characteristics on phase separation and domain formation in cholesterol-lipid mixtures. , 2005, Biophysical journal.

[22]  P. Carrupt,et al.  Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability. , 2006, Journal of medicinal chemistry.

[23]  Kiyohiko Sugano,et al.  Prediction of human intestinal permeability using artificial membrane permeability. , 2003, International journal of pharmaceutics.

[24]  Edward H. Kerns,et al.  Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization , 2008 .

[25]  D. Begley,et al.  Flavonoid permeability across an in situ model of the blood-brain barrier. , 2004, Free radical biology & medicine.

[26]  H. Galla,et al.  Lipid polarity in brain capillary endothelial cells. , 2001, Endothelium : journal of endothelial cell research.

[27]  J. Brillault,et al.  Prediction of Drug Transport Through the Blood-Brain Barrier in Vivo: A Comparison Between Two in Vitro Cell Models , 2002, Pharmaceutical Research.

[28]  Q. Smith,et al.  A review of blood-brain barrier transport techniques. , 2003, Methods in molecular medicine.

[29]  E. Ikonen,et al.  How cells handle cholesterol. , 2000, Science.

[30]  I. Hidalgo,et al.  Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. , 2005, International journal of pharmaceutics.

[31]  Y. Barenholz,et al.  Dynamics of the hydrocarbon layer in liposomes of lecithin and sphingomyelin containing dicetylphosphate. , 1974, The Journal of biological chemistry.

[32]  K. Audus,et al.  Evidence for 21-aminosteroid association with the hydrophobic domains of brain microvessel endothelial cells. , 1991, Free radical biology & medicine.

[33]  J. Bourre,et al.  Lipid Synthesis by Rat Brain Microvessel Endothelial Cells in Tissue Culture , 1989, Journal of neuropathology and experimental neurology.

[34]  C. Rousselle,et al.  In Vivo Saturation of the Transport of Vinblastine and Colchicine by P-Glycoprotein at the Rat Blood–Brain Barrier , 2003, Pharmaceutical Research.

[35]  A A Spector,et al.  Membrane lipid composition and cellular function. , 1985, Journal of lipid research.

[36]  Bill J Smith,et al.  Progress in Brain Penetration Evaluation in Drug Discovery and Development , 2008, Journal of Pharmacology and Experimental Therapeutics.

[37]  H. Vromans,et al.  Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. , 2003, International journal of pharmaceutics.

[38]  Q. Smith.  Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. , 1996, Pharmaceutical biotechnology.

[39]  W. Pardridge,et al.  Log(BB), PS products and in silico models of drug brain penetration. , 2004, Drug discovery today.

[40]  C. Bigogno,et al.  Evaluation of in vitro brain penetration: optimized PAMPA and MDCKII-MDR1 assay comparison. , 2007, International journal of pharmaceutics.

[41]  Anders Tunek,et al.  High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. , 2007, Journal of medicinal chemistry.

[42]  Xingrong Liu,et al.  Strategies to optimize brain penetration in drug discovery. , 2005, Current opinion in drug discovery & development.

[43]  Li Di,et al.  High throughput artificial membrane permeability assay for blood-brain barrier. , 2003, European journal of medicinal chemistry.

[44]  Alex Avdeef,et al.  The rise of PAMPA , 2005, Expert opinion on drug metabolism & toxicology.

[45]  Jörg Huwyler,et al.  In silico prediction of brain and CSF permeation of small molecules using PLS regression models. , 2008, European journal of medicinal chemistry.

[46]  W. Williams,et al.  Cerebral microvascular and parenchymal phospholipid composition in the mouse , 1988, Neurochemical Research.

[47]  J. Nutt,et al.  Strategies to advance translational research into brain barriers , 2008, The Lancet Neurology.

[48]  S. Rapoport,et al.  An in situ brain perfusion technique to study cerebrovascular transport in the rat. , 1984, The American journal of physiology.

[49]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[50]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[51]  M Gumbleton,et al.  Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. , 2001, Journal of pharmaceutical sciences.

[52]  J. Polli,et al.  IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES , 2006, Drug Metabolism and Disposition.

[53]  G. Meer,et al.  Two strains of the Madin‐Darby canine kidney (MDCK) cell line have distinct glycosphingolipid compositions. , 1986, The EMBO journal.

[54]  Kin-Kai Hwang,et al.  A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. , 2002, European journal of medicinal chemistry.

[55]  Phil Jeffrey,et al.  Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction , 2007, Journal of Pharmacology and Experimental Therapeutics.

[56]  Emi Nakashima,et al.  New approaches to in vitro models of blood-brain barrier drug transport. , 2003, Drug discovery today.

[57]  B. Faller,et al.  High-throughput lipophilicity measurement with immobilized artificial membranes. , 2005, Journal of medicinal chemistry.

[58]  Li Di,et al.  Profiling drug-like properties in discovery research. , 2003, Current opinion in chemical biology.

[59]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[60]  N. Abbott.  Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. , 2004, Drug discovery today. Technologies.

[61]  Jiunn H Lin,et al.  How significant is the role of P-glycoprotein in drug absorption and brain uptake? , 2004, Drugs of today.

[62]  Katharina Mertsch and Jochen Maas.  Blood-Brain Barrier Penetration and Drug Development from an Industrial Point of View , 2002 .

[63]  M. Piciotti,et al.  Possible role of the choroid plexus in the supply of brain tissue with polyunsaturated fatty acids , 1997, Neuroscience Letters.

[64]  G. Trugnan,et al.  Differential solubilization of inner plasma membrane leaflet components by Lubrol WX and Triton X-100. , 2008, Biochimica et biophysica acta.

[65]  Bo Feng,et al.  In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.

[66]  Ronald T. Borchardt,et al.  Quantitative Approaches to Delineate Passive Transport Mechanisms in Cell Culture Monolayers , 1999 .